Research programme: OX40 based therapeutics - Genentech

Drug Profile

Research programme: OX40 based therapeutics - Genentech

Alternative Names: Anti-OX40L; CD134; CTB OX40; CTB-134L

Latest Information Update: 17 Apr 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenova Group
  • Class Differentiation antigens; Membrane glycoproteins; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer; Inflammation; Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 26 Apr 2002 Genentech has signed a worldwide licensing agreement with Xenova
  • 22 Nov 2001 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)
  • 28 Jun 2001 Cantab Pharmaceuticals has been acquired by Xenova Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top